Enabling Scalable Comprehensive Genomic Profiling from FFPE Samples

Publication Title

Illumina

Authors

Brian D. Piening, Molecular Genomics Laboratory, Providence Portland Medical Center, Portland, OR; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Cancer Center, Portland, OR.Follow

Document Type

Presentation

Publication Date

6-9-2020

Keywords

oregon; portland; chiles; genomics

Abstract

Comprehensive genomic profiling (CGP) is becoming standard of care for cancer and allows pathology labs to consolidate individual biomarkers into a single NGS assay. It enables the assessment of all key biomarkers cited in guidelines and clinical trials using a minimal amount of formalin-fixed, paraffin-embedded (FFPE) tissue while increasing the chance of finding a positive biomarker for every sample.

Illumina’s TruSight Oncology 500 High-Throughput (TSO500 HT)assay enables labs to perform in-house CGP with scalability on a NovaSeq 6000 platform.

In this CellPress webinar, Brian Piening of Providence Cancer Center will discuss why his team decided to implement in-house CGP and will share analytical performance data from their TSO500_HT runs. He will also provide details of the center’s end-to-end workflow, including the data analysis flow and how they build their final reports.

Area of Special Interest

Cancer

Specialty/Research Institute

Earle A. Chiles Research Institute

Specialty/Research Institute

Oncology